Scientists hunt for biomarkers to personalize cancer therapy
NCT ID NCT00628368
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study analyzed tumor and blood samples from 160 people with esophageal or rectal cancer. Researchers looked for genetic markers in the EGFR signaling pathway that might predict how well a patient responds to chemoradiotherapy given before surgery. The goal is to better understand which patients benefit most from this treatment approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which patients will respond well to chemoradiotherapy, leading to more personalized treatment plans.
- What could go wrong
- This is an observational, lab-based study, not a treatment trial. The findings may not translate into immediate clinical changes or benefit participants directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, 34298, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a new drug combo revive Immunotherapy's power against resistant tumors?